{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carfilzomib&page=17", "query": { "intervention": "carfilzomib", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 193, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carfilzomib&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=carfilzomib&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T20:55:09.209Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01029054", "title": "Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "carfilzomib, lenalidomide plus dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2009-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • St Louis, Missouri • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01029054" }, { "nct_id": "NCT02336815", "title": "Selinexor Treatment of Refractory Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2015-05-26", "completion_date": "2019-07-26", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02336815" }, { "nct_id": "NCT05438043", "title": "A Study of Daratumumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 213, "start_date": "2022-12-15", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 7, "location_summary": "Miami, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05438043" }, { "nct_id": "NCT01665794", "title": "Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2012-08-13", "completion_date": "2025-11-14", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 4, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01665794" }, { "nct_id": "NCT07715903", "title": "Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms", "Neoplasms", "Intrahepatic Cholangiocarcinoma", "Adrenocortical Carcinoma", "Metastasis, Neoplasm" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2026-10-22", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07715903" }, { "nct_id": "NCT02293109", "title": "Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "carfilzomib", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mehrdad Abedi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 10, "start_date": "2015-12-17", "completion_date": "2018-01-11", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02293109" }, { "nct_id": "NCT02206425", "title": "Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ascorbic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "PLD", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-09", "completion_date": "2018-03-06", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 12, "location_summary": "Bakersfield, California • Concord, California • Encinitas, California + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206425" }, { "nct_id": "NCT02148913", "title": "Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cohort 1: Carfilzomib 15 mg/m2", "type": "DRUG" }, { "name": "Cohort 2: Carfilzomib 20 mg/m2", "type": "DRUG" }, { "name": "Cohort 2b: Carfilzomib 20 mg/m2", "type": "DRUG" }, { "name": "Cohort 3b: Carfilzomib 27 mg/m2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corewell Health West", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-06", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 1, "location_summary": "Grand Rapids, Michigan", "locations": [ { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02148913" }, { "nct_id": "NCT02257476", "title": "Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Malignancies" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-08", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257476" }, { "nct_id": "NCT03275285", "title": "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "isatuximab SAR650984", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2017-10-25", "completion_date": "2025-01-03", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-19T20:55:09.209Z", "location_count": 2, "location_summary": "San Francisco, California • Spartanburg, South Carolina", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275285" } ] }